Literature DB >> 7642472

O6-alkylguanine-DNA alkyltransferase. A target for the modulation of drug resistance.

S L Gerson1, J K Willson.   

Abstract

The DNA repair protein, O6-alkylguanine DNA alkyltransferase, is a major contributor to the resistance to the nitrosourea, triazine, and tetrazine class of alkylating agents. Many tumor cells and primary tumor samples contain high levels of this protein, although a great deal of heterogeneity exists between and within tumors. Inhibition of the alkyl-transferase by O6-benzylguanine results in significant potentiation of the cytotoxic effects of these chemotherapeutic agents, generating responses in human tumor xenografts that are completely resistant to nitrosoureas alone. These studies may rekindle the interest in the nitrosourea class of alkylating agents and stimulate the search for inhibitors of other mechanisms of chemotherapy resistance.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7642472

Source DB:  PubMed          Journal:  Hematol Oncol Clin North Am        ISSN: 0889-8588            Impact factor:   3.722


  12 in total

1.  DNA repair protein O6-alkylguanine-DNA alkyltransferase is phosphorylated by two distinct and novel protein kinases in human brain tumour cells.

Authors:  S R Mullapudi; F Ali-Osman; J Shou; K S Srivenugopal
Journal:  Biochem J       Date:  2000-10-15       Impact factor: 3.857

2.  4-nitrobenzyloxycarbonyl derivatives of O(6)-benzylguanine as hypoxia-activated prodrug inhibitors of O(6)-alkylguanine-DNA alkyltransferase (AGT), which produces resistance to agents targeting the O-6 position of DNA guanine.

Authors:  Rui Zhu; Mao-Chin Liu; Mei-Zhen Luo; Philip G Penketh; Raymond P Baumann; Krishnamurthy Shyam; Alan C Sartorelli
Journal:  J Med Chem       Date:  2011-10-17       Impact factor: 7.446

Review 3.  Direct reversal of DNA alkylation damage.

Authors:  Yukiko Mishina; Erica M Duguid; Chuan He
Journal:  Chem Rev       Date:  2006-02       Impact factor: 60.622

4.  Levetiracetam enhances p53-mediated MGMT inhibition and sensitizes glioblastoma cells to temozolomide.

Authors:  George C Bobustuc; Cheryl H Baker; Arati Limaye; Wayne D Jenkins; Gary Pearl; Nicholas G Avgeropoulos; Santhi D Konduri
Journal:  Neuro Oncol       Date:  2010-06-04       Impact factor: 12.300

Review 5.  Molecular status of pituitary carcinoma and atypical adenoma that contributes the effectiveness of temozolomide.

Authors:  Akira Matsuno; Mineko Murakami; Katsumi Hoya; Shoko M Yamada; Shinya Miyamoto; So Yamada; Jae-Hyun Son; Hajime Nishido; Fuyuaki Ide; Hiroshi Nagashima; Mutsumi Sugaya; Toshio Hirohata; Akiko Mizutani; Hiroko Okinaga; Yudo Ishii; Shigeyuki Tahara; Akira Teramoto; R Yoshiyuki Osamura
Journal:  Med Mol Morphol       Date:  2013-08-17       Impact factor: 2.309

6.  Phase I clinical trial of O6-benzylguanine and topical carmustine in the treatment of cutaneous T-cell lymphoma, mycosis fungoides type.

Authors:  Narin Apisarnthanarax; Gary S Wood; Seth R Stevens; Sean Carlson; Derek V Chan; Lili Liu; Sarolta K Szabo; Pingfu Fu; Anita C Gilliam; Stanton L Gerson; Scot C Remick; Kevin D Cooper
Journal:  Arch Dermatol       Date:  2012-05

7.  Retroviral transduction of a mutant methylguanine DNA methyltransferase gene into human CD34 cells confers resistance to O6-benzylguanine plus 1,3-bis(2-chloroethyl)-1-nitrosourea.

Authors:  J S Reese; O N Koç; K M Lee; L Liu; J A Allay; W P Phillips; S L Gerson
Journal:  Proc Natl Acad Sci U S A       Date:  1996-11-26       Impact factor: 11.205

Review 8.  Targeting microtubules by natural agents for cancer therapy.

Authors:  Eiman Mukhtar; Vaqar Mustafa Adhami; Hasan Mukhtar
Journal:  Mol Cancer Ther       Date:  2014-01-16       Impact factor: 6.261

9.  A Drug Screening Pipeline Using 2D and 3D Patient-Derived In Vitro Models for Pre-Clinical Analysis of Therapy Response in Glioblastoma.

Authors:  Sakthi Lenin; Elise Ponthier; Kaitlin G Scheer; Erica C F Yeo; Melinda N Tea; Lisa M Ebert; Mariana Oksdath Mansilla; Santosh Poonnoose; Ulrich Baumgartner; Bryan W Day; Rebecca J Ormsby; Stuart M Pitson; Guillermo A Gomez
Journal:  Int J Mol Sci       Date:  2021-04-21       Impact factor: 5.923

10.  The Fanconi anemia (FA) pathway confers glioma resistance to DNA alkylating agents.

Authors:  Clark C Chen; Toshiyasu Taniguchi; Alan D'Andrea
Journal:  J Mol Med (Berl)       Date:  2007-01-13       Impact factor: 5.606

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.